Mariangela Prada
Mariangela Prada has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Claudia Bertozzi
Intexo Società Benefit – A PLG company, Milan/Rome - Italy
1 shared publication- Claudia Passante
PLG – ProductLife Group, Milan - Italy
1 shared publication - Entela Xoxi
Altems Advisory, spin-off dell’Università Cattolica del Sacro Cuore, Rome - Italy
1 shared publication - Giovanni Callegaro
Intexo Società Benefit – A PLG company, Milan/Rome - Italy
1 shared publication - Giulia Fagnocchi
Intexo Società Benefit – A PLG company, Milan/Rome - Italy
1 shared publication - Rossella Di Bidino
Università Cattolica del Sacro Cuore
1 shared publication
Latest Publications
- Open Access
- 15 July 2026
- Published by Aboutscience Srl in Global and Regional Health Technology Assessment
- Vol. 13 (1) , 221-229
Exploring the current and future role of artificial intelligence in pharmaceutical market access: insights from a European survey
Introduction: Artificial Intelligence (AI) is rapidly expanding across the pharmaceutical value chain; however,empirical evidence on its application in Market Access (MA) remains limited. Given the strategic relevance andregulatory complexity of MA, understanding current AI adoption and perception represents a significant evidencegap. This study provides one of the first exploratory, European-focused assessments specifically investigating therole of AI in pharmaceutical MA.Methods: A structured, closed survey was conducted among European pharmaceutical MA executives and seniorleaders. The questionnaire investigated AI adoption levels, governance and implementation models, perceivedbenefits and barriers, and current and future applications, with a focus on MA activities. The survey was distributedbetween June and November 2025 through targeted professional outreach and conference-based datacollection.Results: Fifty responses were collected. Overall, 44% of respondents reported structural AI implementationwithin their organizations, with MA being the most impacted function (59%), contrasting with previous analyseswhere MA was among the least affected areas. AI adoption was strongly linked to company size, favoring largecompanies. Key barriers to AI adoption in MA included limited availability of high-quality data, data integrationchallenges, lack of internal expertise, and regulatory uncertainty. Reported benefits were mainly operational,while respondents identified strong future potential in market analysis, forecasting, health economics and outcomes research, and pricing and reimbursement strategy.Conclusions: AI is increasingly perceived as a valuable enabler in MA, although adoption remains heterogeneousand at an intermediate maturity stage. Effective integration requires robust governance, regulatory clarity, andAI-generated insights that support—rather than replace—human expertise.
- 15 July 2026
- Published by Aboutscience Srl in Global and Regional Health Technology Assessment
- Vol. 13 (1) , 221-229
Open AccessExploring the current and future role of artificial intelligence in pharmaceutical market access: insights from a European survey
Introduction: Artificial Intelligence (AI) is rapidly expanding across the pharmaceutical value chain; however,empirical evidence on its application in Market Access (MA) remains limited. Given the strategic relevance andregulatory complexity of MA, understanding current AI adoption and perception represents a significant evidencegap. This study provides one of the first exploratory, European-focused assessments specifically investigating therole of AI in pharmaceutical MA.Methods: A structured, closed survey was conducted among European pharmaceutical MA executives and seniorleaders. The questionnaire investigated AI adoption levels, governance and implementation models, perceivedbenefits and barriers, and current and future applications, with a focus on MA activities. The survey was distributedbetween June and November 2025 through targeted professional outreach and conference-based datacollection.Results: Fifty responses were collected. Overall, 44% of respondents reported structural AI implementationwithin their organizations, with MA being the most impacted function (59%), contrasting with previous analyseswhere MA was among the least affected areas. AI adoption was strongly linked to company size, favoring largecompanies. Key barriers to AI adoption in MA included limited availability of high-quality data, data integrationchallenges, lack of internal expertise, and regulatory uncertainty. Reported benefits were mainly operational,while respondents identified strong future potential in market analysis, forecasting, health economics and outcomes research, and pricing and reimbursement strategy.Conclusions: AI is increasingly perceived as a valuable enabler in MA, although adoption remains heterogeneousand at an intermediate maturity stage. Effective integration requires robust governance, regulatory clarity, andAI-generated insights that support—rather than replace—human expertise.
- Open Access
- 4 March 2026
- Published by Aboutscience Srl in Global and Regional Health Technology Assessment
- Vol. 13 (1) , 146-153
Procedural activity and dynamics of the new Italian Scientific and Economic Committee (CSE): a one-year observational analysis
Introduction: In January 2024, the Commissione Scientifica ed Economica (CSE) became the national body responsible for the integrated scientific and economic evaluation of medicines in Italy. This study provides the firstsystematic description of the CSE’s activity during its initial operational year, focusing on procedural workload,timelines, and negotiation outcomes.Methods: All publicly available “Esiti CSE” documents published by the Italian Medicines Agency (AIFA) betweenApril 2024 and April 2025 were manually extracted and validated. Each record included the negotiation typology(TN-1 to TN-8), outcome, and iter duration. Descriptive analyses summarised distributions, median and meandurations, deferral rates, and trends over time.Results: A total of 641 procedures (523 products, 446 INNs) generated 2,145 individual outcomes. Argomentorinviato (deferral) was the most frequent outcome (55.7% of all decisions; 51% of procedures). The average procedure involved 1.9 deferrals, and 83% experienced at least one. Mean overall duration was 269 days (median196; IQR 133–350), with the longest timelines for TN-1 and TN-4 negotiations (298 and 322 days, respectively).Oncology (L01, L04) and metabolic agents (A10) showed the greatest variability, while antivirals (J05) recordedthe longest average duration (549 days) but a lower incidence of deferral.Conclusions: The first year of CSE activity reveals a high workload, variable timelines, and frequent deferrals, reflecting the complexity of integrating scientific and economic assessment within a single body. The results provide an empirical baseline for future monitoring and underscore the need for refinement of governance arrangements and procedural transparency in AIFA’s new framework.
- 4 March 2026
- Published by Aboutscience Srl in Global and Regional Health Technology Assessment
- Vol. 13 (1) , 146-153
Open AccessProcedural activity and dynamics of the new Italian Scientific and Economic Committee (CSE): a one-year observational analysis
Introduction: In January 2024, the Commissione Scientifica ed Economica (CSE) became the national body responsible for the integrated scientific and economic evaluation of medicines in Italy. This study provides the firstsystematic description of the CSE’s activity during its initial operational year, focusing on procedural workload,timelines, and negotiation outcomes.Methods: All publicly available “Esiti CSE” documents published by the Italian Medicines Agency (AIFA) betweenApril 2024 and April 2025 were manually extracted and validated. Each record included the negotiation typology(TN-1 to TN-8), outcome, and iter duration. Descriptive analyses summarised distributions, median and meandurations, deferral rates, and trends over time.Results: A total of 641 procedures (523 products, 446 INNs) generated 2,145 individual outcomes. Argomentorinviato (deferral) was the most frequent outcome (55.7% of all decisions; 51% of procedures). The average procedure involved 1.9 deferrals, and 83% experienced at least one. Mean overall duration was 269 days (median196; IQR 133–350), with the longest timelines for TN-1 and TN-4 negotiations (298 and 322 days, respectively).Oncology (L01, L04) and metabolic agents (A10) showed the greatest variability, while antivirals (J05) recordedthe longest average duration (549 days) but a lower incidence of deferral.Conclusions: The first year of CSE activity reveals a high workload, variable timelines, and frequent deferrals, reflecting the complexity of integrating scientific and economic assessment within a single body. The results provide an empirical baseline for future monitoring and underscore the need for refinement of governance arrangements and procedural transparency in AIFA’s new framework.